170 related articles for article (PubMed ID: 37634844)
1. Revisiting the Utility of Granulocyte Colony-Stimulating Factor Post-Autologous Hematopoietic Stem Cell Transplantation for Outpatient-Based Transplantations.
Portuguese AJ; Holmberg L; Hill GR; Lee SJ; Green DJ; Mielcarek M; Gooley T; Yeh AC
Transplant Cell Ther; 2023 Nov; 29(11):696.e1-696.e7. PubMed ID: 37634844
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of deferred dosing of granulocyte colony-stimulating factor in autologous hematopoietic transplantation for multiple myeloma.
Cox JE; Campos S; Wu J; May R; Liu H; Ramos CA; Carrum G; Heslop HE; Brenner MK; Kamble RT
Bone Marrow Transplant; 2014 Feb; 49(2):219-22. PubMed ID: 24096822
[TBL] [Abstract][Full Text] [Related]
3. Prospective randomized comparative observation of single- versus split-dose lenograstim to enhance engraftment after autologous stem cell transplantation in patients with multiple myeloma or non-Hodgkin's lymphoma.
Jang G; Ko OB; Kim S; Lee DH; Huh J; Suh C
Transfusion; 2008 Apr; 48(4):640-6. PubMed ID: 18194384
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas.
Poiré X; Kline J; Grinblatt D; Zimmerman T; Conner K; Muhs C; Gajewski T; Van Besien K; Smith SM
Leuk Lymphoma; 2010 Jul; 51(7):1241-50. PubMed ID: 20496994
[TBL] [Abstract][Full Text] [Related]
5. Transplanted CD34(+) cell dose is associated with long-term platelet count recovery following autologous peripheral blood stem cell transplant in patients with non-Hodgkin lymphoma or multiple myeloma.
Stiff PJ; Micallef I; Nademanee AP; Stadtmauer EA; Maziarz RT; Bolwell BJ; Bridger G; Marulkar S; Hsu FJ; DiPersio JF
Biol Blood Marrow Transplant; 2011 Aug; 17(8):1146-53. PubMed ID: 21126595
[TBL] [Abstract][Full Text] [Related]
6. Granulocyte Colony-Stimulating Factor Use after Autologous Peripheral Blood Stem Cell Transplantation: Comparison of Two Practices.
Singh AD; Parmar S; Patel K; Shah S; Shore T; Gergis U; Mayer S; Phillips A; Hsu JM; Niesvizky R; Mark TM; Pearse R; Rossi A; van Besien K
Biol Blood Marrow Transplant; 2018 Feb; 24(2):288-293. PubMed ID: 29061534
[TBL] [Abstract][Full Text] [Related]
7. High dose therapy and autologous stem cell transplantation for human immunodeficiency virus-associated non-Hodgkin lymphoma in the era of highly active antiretroviral therapy.
Molina A; Krishnan AY; Nademanee A; Zabner R; Sniecinski I; Zaia J; Forman SJ
Cancer; 2000 Aug; 89(3):680-9. PubMed ID: 10931469
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high-dose melphalan and autologous stem cell transplantation.
Martino M; Gori M; Porto G; Pellicano M; Santoro L; Verduci C; Canale FA; Loteta B; Moscato T; Alati C; Ieracitano MC; Cuzzocrea A; Altomonte M; Florenzano MT; Morabito A; Irrera G; Naso V; Pugliese M; Console G; Ferreri A; Imbalzano L; Tripepi G; Pitino A
Ann Hematol; 2023 Jul; 102(7):1915-1925. PubMed ID: 37079070
[TBL] [Abstract][Full Text] [Related]
9. Successful Mobilization of Autologous Hematopoietic Peripheral Blood Stem Cells after Salvage Chemotherapy in Patients with Low CD34 Blood Cell Counts.
Holmberg LA; Linenberger M; Connelly-Smith L
Transplant Cell Ther; 2022 Nov; 28(11):754-759. PubMed ID: 36002104
[TBL] [Abstract][Full Text] [Related]
10. Additional plerixafor to granulocyte colony-stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in people with malignant lymphoma or multiple myeloma.
Hartmann T; Hübel K; Monsef I; Engert A; Skoetz N
Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD010615. PubMed ID: 26484982
[TBL] [Abstract][Full Text] [Related]
11. A Prospective, Randomized Trial Examining the Use of G-CSF Versus No G-CSF in Patients Post-Autologous Transplantation.
Grosso D; Leiby B; Wilde L; Carabasi M; Filicko-O'Hara J; O'Hara W; Wagner JL; Mateja G; Alpdogan O; Binder A; Kasner M; Keiffer G; Klumpp T; Martinez UO; Palmisiano N; Porcu P; Gergis U; Flomenberg N
Transplant Cell Ther; 2022 Dec; 28(12):831.e1-831.e7. PubMed ID: 36167307
[TBL] [Abstract][Full Text] [Related]
12. Risk of febrile neutropenia among patients with multiple myeloma or lymphoma who undergo inpatient versus outpatient autologous stem cell transplantation: a systematic review and meta-analysis.
Owattanapanich W; Suphadirekkul K; Kunacheewa C; Ungprasert P; Prayongratana K
BMC Cancer; 2018 Nov; 18(1):1126. PubMed ID: 30445930
[TBL] [Abstract][Full Text] [Related]
13. Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials.
Chhabra S; Callander N; Watts NL; Costa LJ; Thapa B; Kaufman JL; Laubach J; Sborov DW; Reeves B; Rodriguez C; Chari A; Silbermann R; Anderson LD; Bal S; Dhakal B; Nathwani N; Shah N; Medvedova E; Bumma N; Holstein SA; Costello C; Jakubowiak A; Wildes TM; Schmidt T; Orlowski RZ; Shain KH; Cowan AJ; Dholaria B; Cornell RF; Jerkins JH; Pei H; Cortoos A; Patel S; Lin TS; Usmani SZ; Richardson PG; Voorhees PM
Transplant Cell Ther; 2023 Mar; 29(3):174.e1-174.e10. PubMed ID: 36494017
[TBL] [Abstract][Full Text] [Related]
14. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function.
Alexander ET; Towery JA; Miller AN; Kramer C; Hogan KR; Squires JE; Stuart RK; Costa LJ
Transfusion; 2011 Sep; 51(9):1995-2000. PubMed ID: 21392017
[TBL] [Abstract][Full Text] [Related]
15. Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report.
Micallef IN; Stiff PJ; Nademanee AP; Maziarz RT; Horwitz ME; Stadtmauer EA; Kaufman JL; McCarty JM; Vargo R; Cheverton PD; Struijs M; Bolwell B; DiPersio JF
Biol Blood Marrow Transplant; 2018 Jun; 24(6):1187-1195. PubMed ID: 29410180
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma.
Stewart DA; Smith C; MacFarland R; Calandra G
Biol Blood Marrow Transplant; 2009 Jan; 15(1):39-46. PubMed ID: 19135941
[TBL] [Abstract][Full Text] [Related]
17. Granulocyte colony-stimulating factor utilization postautologous hematopoietic stem cell transplant in multiple myeloma patients: Does one size fit all?
Jackson ER; Jared JR; Piccolo JK; Woo KM; Mably MS; Reed MP; Callander NS
J Oncol Pharm Pract; 2019 Jul; 25(5):1135-1141. PubMed ID: 29890920
[TBL] [Abstract][Full Text] [Related]
18. Biosimilar granulocyte colony-stimulating factor is effective in reducing the duration of neutropenia after autologous peripheral blood stem cell transplantation.
Cioch M; Jawniak D; Kotwica K; Wach M; Mańko J; Gorący A; Klimek P; Mazurkiewicz E; Jarosz P; Hus M
Transplant Proc; 2014 Oct; 46(8):2882-4. PubMed ID: 25380941
[TBL] [Abstract][Full Text] [Related]
19. The avoidance of G-CSF and the addition of prophylactic corticosteroids after autologous stem cell transplantation for multiple myeloma patients appeal for the at-home setting to reduce readmission for neutropenic fever.
Rodríguez-Lobato LG; Martínez-Roca A; Castaño-Díez S; Palomino-Mosquera A; Gutiérrez-García G; Pedraza A; Suárez-Lledó M; Rovira M; Martínez C; Fernández de Larrea C; Cibeira MT; Rosiñol L; Lozano E; Marín P; Cid J; Lozano M; Moreno-Castaño AB; Palomo M; Díaz-Ricart M; Gallego C; Hernando A; Segura S; Carreras E; Urbano-Ispizua Á; Bladé J; Fernández-Avilés F
PLoS One; 2020; 15(11):e0241778. PubMed ID: 33147257
[TBL] [Abstract][Full Text] [Related]
20. Flat-dose granulocyte colony-stimulating factor evaluation after autologous hematopoietic stem cell transplant in multiple myeloma patients: Does one dose fit all?
Kim OM; Jared JR; Hennes ER; Ninos CL; Przybylski DJ; Callander NS
J Oncol Pharm Pract; 2021 Oct; 27(7):1716-1722. PubMed ID: 33100179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
